
|Articles|March 7, 2010
- August 2009
- Volume 3
- Issue 8
Update from BIG 1-98, Studies on PARP Inhibitors, Bevacizumab & GI Perforation, Oral Mucositis, Casopitant in CINV, and more
Author(s)Onclive Team
Key Takeaways
Advertisement
Articles in this issue
over 16 years ago
Is PFS Enough for Approval?, PharmaFocus: Velcade, etc.over 16 years ago
Treating Chemotherapy-Induced Emesisover 16 years ago
Highlights from European Hematology AssociationAdvertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5







































































